tiprankstipranks
Advertisement
Advertisement

BCAX Stock Latest News

Bicara Therapeutics’ Earnings Call Highlights Pivotal Pivot
Company AnnouncementsBicara Therapeutics’ Earnings Call Highlights Pivotal Pivot
7d ago
BCAX
Bicara Therapeutics management to meet with Citizens
PremiumThe Fly
Bicara Therapeutics management to meet with Citizens
11d ago
BCAX
Bicara Therapeutics price target raised to $16 from $11 at Wells Fargo
PremiumThe Fly
Bicara Therapeutics price target raised to $16 from $11 at Wells Fargo
13d ago
BCAX
Buy Rating Backed by Ficerafusp Alfa Milestones and Strong Cash Runway Supporting $42 Target Price
PremiumRatings
Buy Rating Backed by Ficerafusp Alfa Milestones and Strong Cash Runway Supporting $42 Target Price
13d ago
BCAX
Bicara Therapeutics price target raised to $16 from $14 at Goldman Sachs
PremiumThe Fly
Bicara Therapeutics price target raised to $16 from $14 at Goldman Sachs
13d ago
BCAX
Morning Movers: Sysco dips following deal to acquire Jetro Restaurant Depot
PremiumThe FlyMorning Movers: Sysco dips following deal to acquire Jetro Restaurant Depot
14d ago
IQ
SR
Bicara Therapeutics reports Q4 EPS (68c), consensus (65c)
Premium
The Fly
Bicara Therapeutics reports Q4 EPS (68c), consensus (65c)
14d ago
BCAX
BofA starts Bicara Therapeutics with a Buy on head and neck cancer potential
Premium
The Fly
BofA starts Bicara Therapeutics with a Buy on head and neck cancer potential
19d ago
BCAX
Bicara Therapeutics initiated with a Buy at BofA
PremiumThe Fly
Bicara Therapeutics initiated with a Buy at BofA
19d ago
BCAX
Is BCAX a Buy, Before Earnings?
PremiumPre-Earnings
Is BCAX a Buy, Before Earnings?
20d ago
BCAX
Bicara Therapeutics announces inducement grants
PremiumThe Fly
Bicara Therapeutics announces inducement grants
1M ago
BCAX
Bicara Therapeutics Strengthens Finances with Equity Offering
PremiumCompany Announcements
Bicara Therapeutics Strengthens Finances with Equity Offering
2M ago
8K
BCAX
Bicara Therapeutics 7.175M share Spot Secondary priced at $16.00
PremiumThe FlyBicara Therapeutics 7.175M share Spot Secondary priced at $16.00
2M ago
BCAX
Bicara Therapeutics announces proposed offering of $150M in common stock
Premium
The Fly
Bicara Therapeutics announces proposed offering of $150M in common stock
2M ago
BCAX
Bicara: Best-in-Class Potential for Ficerafusp Alfa in First-Line HPV-Negative Head and Neck Cancer Supports Buy Rating and $30 Target
Premium
Ratings
Bicara: Best-in-Class Potential for Ficerafusp Alfa in First-Line HPV-Negative Head and Neck Cancer Supports Buy Rating and $30 Target
2M ago
BCAX
Bicara announces promising Phase 1b ficerafusp alfa results
PremiumCompany Announcements
Bicara announces promising Phase 1b ficerafusp alfa results
2M ago
8K
BCAX
Bicara moved to Neutral from Early-Stage Biotech at Goldman Sachs
PremiumThe Fly
Bicara moved to Neutral from Early-Stage Biotech at Goldman Sachs
2M ago
BCAX
Bicara Therapeutics announces inducement grants
PremiumThe Fly
Bicara Therapeutics announces inducement grants
2M ago
BCAX
Bicara Therapeutics initiated with an Outperform at Citizens
PremiumThe Fly
Bicara Therapeutics initiated with an Outperform at Citizens
2M ago
BCAX
BCAX: De-Risked FORTIFI-HN01 Path, Differentiated Ficera Profile, and Solid Cash Runway Underpin Buy Rating and $28 Target
PremiumRatingsBCAX: De-Risked FORTIFI-HN01 Path, Differentiated Ficera Profile, and Solid Cash Runway Underpin Buy Rating and $28 Target
3M ago
BCAX
Maintaining a Buy on Bicara Therapeutics: De‑Risked Phase 3 Path for Ficerafusp Alfa Supports $40 Target and $2.2B Valuation
Premium
Ratings
Maintaining a Buy on Bicara Therapeutics: De‑Risked Phase 3 Path for Ficerafusp Alfa Supports $40 Target and $2.2B Valuation
3M ago
BCAX
Bicara Sets Phase 3 Path for Ficerafusp Alfa
Premium
Company Announcements
Bicara Sets Phase 3 Path for Ficerafusp Alfa
3M ago
8K
BCAX

Trending

Name
Price
Price Change
SPX
S&P 500
―
DJIA
Dow Jones
―
NDX
Nasdaq 100
―
More Trending Stocks >